Our inaugural Payer Report Series is launching soon! The first report of this series, coming out later this month, will be a two-part payer landscape report featuring 1) a landscape overview and 2) in-depth yet succinct profiles on six of the largest vertical payers: Humana, Centene, Elevance Health (formerly Anthem), Cigna, UnitedHealth Group, and CVS Health.
As these payers continue to grow and “verticalize,” they are capturing an increasingly large share of national healthcare expenditures and will impact how every stakeholder in our health system does business. But what exactly are they doing and how successful are their verticalization efforts?
We combed through the data and financial sources to deliver a report sure to elevate our sponsors’ understanding of how each vertical payer’s overall structure, recent healthcare services investments, business size and footprint, and financial model will impact the overall organization. If you want to know how your company’s priorities and business operations need to adapt as these vertical payers grow, be sure to keep an eye on your inbox for the release of this incredibly valuable report!
Sneak Peek
UnitedHealth Group is arguably the most extensive and integrated vertical payer to date with a high “verticalization maturity” – the Optum Brand is more than a decade in the making and has a huge network of both employed healthcare practitioners and value-based provider arrangements
UnitedHealth is investing in oncology care services, with a focus on oncology value-based programs, dedicated Optum cancer clinics, the Optum Cancer Centers of Excellence program, and its Optum infusion pharmacies
Optum Insight sells extensive datasets and analytics offerings, helping to make Optum (for now) the leader in providing healthcare information among its vertical payer rivals
We can’t wait to share this report with you soon! As always, please reach out with any comments or questions you have.
All the best...
-- HMP Market Access Insights Team
In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van DenburgIn part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.
Lee Blansett